{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:00:06Z","timestamp":1772118006850,"version":"3.50.1"},"reference-count":21,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["mol clin onc"],"DOI":"10.3892\/mco.2017.1519","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T12:13:54Z","timestamp":1511784834000},"source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report"],"prefix":"10.3892","author":[{"given":"Rammohan","family":"Prasanna","sequence":"first","affiliation":[{"name":"Consultant Medical Oncologist, Department of Medical Oncology, CBCC-GVN Cancer Center, Tiruchirapalli, Tamil Nadu 620005, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Bunger","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs and Clinical Development, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 380059, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mujtaba","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs and Clinical Development, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 380059, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"key20200713201648_b1-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/0019-557X.128150","article-title":"Breast and cervical cancer risk in India: An update","volume":"58","author":"Asthana","year":"2014","journal-title":"Indian J Public Health"},{"key":"key20200713201648_b2-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cogc.2014.12.003","article-title":"Feasibility of Concurrent Chemoradiation in Cervical Cancer Patients From Rural Background","volume":"7","author":"Harjani","year":"2014","journal-title":"Clin Ovarian Other Gynecol Cancer"},{"key":"key20200713201648_b3-mco-0-0-1519","first-page":"219","article-title":"The magnitude of cancer cervix in India","volume":"130","author":"Nandakumar","year":"2009","journal-title":"Indian J Med Res"},{"key":"key20200713201648_b4-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4103\/0971-5851.195751","article-title":"Burden of cervical cancer and role of screening in India","volume":"37","author":"Bobdey","year":"2016","journal-title":"Indian J Med Paediatr Oncol"},{"key":"key20200713201648_b5-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.critrevonc.2016.11.006","article-title":"Management of patients with recurrent\/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review","volume":"108","author":"Boussios","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20200713201648_b6-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","article-title":"Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer","volume":"340","author":"Morris","year":"1999","journal-title":"N Engl J Med"},{"key":"key20200713201648_b7-mco-0-0-1519","author":"National Cancer Institute","journal-title":"NCI Issues Clinical Announcement on Cervical Cancer: Chemotherapy Plus Radiation Improves Survival"},{"key":"key20200713201648_b8-mco-0-0-1519","first-page":"1563","article-title":"Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer","volume":"20","author":"Takekida","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"key20200713201648_b9-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jfma.2012.10.021","article-title":"The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy","volume":"114","author":"Chen","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"key20200713201648_b10-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1006\/gyno.1998.5140","article-title":"In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers","volume":"71","author":"Monk","year":"1998","journal-title":"Gynecol Oncol"},{"key":"key20200713201648_b11-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3892\/mco.2017.1147","article-title":"Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report","volume":"6","author":"Naik","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"key20200713201648_b12-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clbc.2013.09.011","article-title":"Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients","volume":"14","author":"Ahmad","year":"2014","journal-title":"Clin Breast Cancer"},{"issue":"suppl_9","key":"key20200713201648_b13-mco-0-0-1519","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw579.008","article-title":"Efficacy and safety of a novel nanosomal docetaxel lipid suspension (NDLS) as an anti cancer agent a retrospective study","volume":"27","author":"Ashraf","year":"2016","journal-title":"Ann Oncol."},{"key":"key20200713201648_b14-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3802\/jgo.2012.23.4.235","article-title":"Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer","volume":"23","author":"Kong","year":"2012","journal-title":"J Gynecol Oncol"},{"key":"key20200713201648_b15-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1634\/theoncologist.2012-0455","article-title":"Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks","volume":"18","author":"Nam","year":"2013","journal-title":"Oncologist"},{"key":"key20200713201648_b16-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/02841868909111182","article-title":"A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer","volume":"28","author":"Adams","year":"1989","journal-title":"Acta Oncol"},{"key":"key20200713201648_b17-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/0090-8258(90)90262-J","article-title":"A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: A Southwest Oncology Group study","volume":"39","author":"Weiss","year":"1990","journal-title":"Gynecol Oncol"},{"key":"key20200713201648_b18-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/CAD.0000000000000057","article-title":"Taxanes: Their impact on gynecologic malignancy","volume":"25","author":"Schwab","year":"2014","journal-title":"Anticancer Drugs"},{"key":"key20200713201648_b19-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1006\/gyno.2002.6786","article-title":"Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: A phase I study","volume":"87","author":"Rein","year":"2002","journal-title":"Gynecol Oncol"},{"key":"key20200713201648_b20-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ygyno.2004.11.044","article-title":"Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study","volume":"96","author":"Nagao","year":"2005","journal-title":"Gynecol Oncol"},{"key":"key20200713201648_b21-mco-0-0-1519","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/cam4.454","article-title":"Assessing patients' risk of febrile neutropenia: Is there a correlation between physician-assessed risk and model-predicted risk?","volume":"4","author":"Lyman","year":"2015","journal-title":"Cancer Med"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T19:16:53Z","timestamp":1594667813000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2017.1519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":21,"URL":"https:\/\/doi.org\/10.3892\/mco.2017.1519","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]}}}